CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Ethypharm against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Jul 31, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Dosage Form Containing Oxycodone And NaloxoneEURO CELTIQUEJul 26, 2023
Rapamycin Derivative For Treating Advanced Solid TumoursNOVARTISJan 6, 2023
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-CyclodextrinMERCK SHARP & DOHMEMay 25, 2022
Rapamycin Derivative For Treating Pancreas CancerNOVARTISFeb 14, 2020
Dosage Form Containing Oxycodone And NaloxoneEURO CELTIQUEJan 9, 2020
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISJul 3, 2019
A Rapamycin Derivative For Treating Lung CancerNOVARTISJun 12, 2019
Treatment Of Solid Brain Tumours With A Rapamycin DerivativeNOVARTISDec 22, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 7, 2017
Pharmaceutical Preparation Containing Oxycodone And NaloxoneEURO CELTIQUENov 7, 2017

Explore Ethypharm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Oct 25, 2023Crush-Resistant Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion2

Top competitors of Ethypharm

List of top competitors of Ethypharm based on patent oppositions.